Canary At The Pharma Counter—-Drastically Overbuilt Walgreens Rated A Rare “Sell” By Goldman

Goldman analyst Robert Jones said he doesn’t think these partnerships, even if expanded, will help enough to offset declines in Walgreens’ core retail pharmacy business, according to a research note sent to clients Friday. Jones downgraded Walgreens to “sell” from “hold” Friday.